Remimazolam–Remifentanil Gastroscopy in Severe Obesity Was a Managed Single Case

A successful short procedure in one patient with sleep apnea is evidence of feasibility, not a population safety estimate.

Study findings

A 32-year-old man weighing 145 kg, with a body-mass index of 44.8, hypertension and sleep apnea underwent gastroscopy with remimazolam and remifentanil. The thirty-minute procedure was reported as satisfactory without complications. The report describes preparation and titration as part of the anesthetic plan.

What limits the conclusion

The combination prevents isolation of either drug’s contribution. There was no randomized comparison, and one uneventful exposure cannot exclude respiratory events in other severely obese patients. A reported absence of complications should remain tied to the observation period and monitoring.

Implications for case review

Reconstruct the airway strategy, actual delivery, opioid exposure and interventions before interpreting a case. The patient’s body weight is descriptive information, not a validated dosing formula for another person. Short action and an available antagonist do not independently establish that an unmonitored benzodiazepine–opioid exposure would have the same outcome.

Source and related reading

Source: PMC11269112, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.

Related: Glutaric-Aciduria Anesthesia Case Combined Remimazolam With Metabolic Support.